Recurring Angioedema Without Hives, and Without an Explanation on Any Lab Result
Nothing about her pattern points toward histamine, and everything about her labs rules out the more dangerous bradykinin disorders by name. What's left is a trial-and-error decision neither test can settle.
She has two teenagers whose schedules she keeps track of more precisely than her own, and it was actually her older daughter who noticed the pattern first — a swollen lip or cheek roughly every six to eight weeks for the past year and a half, always without hives, always resolving on its own within a day or two. She mentioned trying over-the-counter diphenhydramine during two of the episodes, without any noticeable effect, though not formally or at a dose anyone would call a real trial.
Her labs close off the more dangerous explanation cleanly: C4, C1-INH level, and C1-INH function are all normal, ruling out the C1-INH-deficient forms of hereditary angioedema specifically. What's left is what Cicardi's HAWK consensus classifies as idiopathic angioedema without wheals — a diagnosis of exclusion her normal complement studies have now earned rather than assumed — and the two reasonable next steps — a formal high-dose antihistamine trial, or a diagnostic-therapeutic trial of a bradykinin-pathway agent captured during a future attack — test two different hypotheses that her own history already leans against one of, however informally that history was gathered.
She takes no ACE inhibitor and has no other chronic medical conditions, no known drug allergies, and no family history of angioedema of any kind — a genuinely clean baseline that removes several of the more common explanations before the visit even starts. She works as a paralegal and has learned to schedule client meetings around her own unpredictable swelling episodes, wearing looser scarves on days she feels a subtle tingling sensation she has come to recognize, by now, as an early warning roughly an hour before visible swelling starts — a prodrome she had never mentioned to a previous clinician because nobody had asked directly whether one existed.
Two trials, neither one a sure answer
Histaminergic causes are still more common overall, even without classic urticaria, and a formal high-dose antihistamine trial is cheap and low-risk. I'd want to try that properly, at an actual therapeutic dose, before reaching for a bradykinin-pathway agent.
I'd push back gently on calling this an untested hypothesis. She's already told us diphenhydramine didn't help during two prior episodes — informal, yes, but it's a real data point pointing away from a histaminergic mechanism, not nothing.
A diagnostic-therapeutic trial of a bradykinin-pathway agent, captured during her next attack, tests the hypothesis her own history hasn't already partly answered. Two limitations, and I want both on the record. Icatibant is approved for hereditary angioedema only, so prescribing it here is off-label and she should hear that from us rather than from a pharmacist. And it's logistical — she'd need the drug on hand and the presence of mind to use it during an actual episode.
That's a fair distinction I hadn't weighted properly — two informal antihistamine failures is more informative than I was treating it. I'd still want a proper high-dose trial for completeness, but I agree it's not the stronger of the two hypotheses left standing.
Agreed: start a proper high-dose antihistamine trial for four weeks while also sending her home with on-demand icatibant to use and document at the first sign of her next attack, rather than choosing one trial over the other.
Both voices explicitly noted this doesn't resolve the underlying uncertainty about her mechanism — it converts an open question into two parallel, real-world tests, with whichever one actually stops the next episode treated as the more informative answer than anything the labs have shown so far.